Acebrophylline-induced generalized fixed drug eruption confirmed by an oral provocation test

2017 ◽  
Vol 5 (5) ◽  
pp. 298
Author(s):  
Su Jin Jeong ◽  
Heon Sa-Kong ◽  
Dong-Hee Park ◽  
Sung Geun Lee ◽  
So Young Jung ◽  
...  
2011 ◽  
Vol 30 (11) ◽  
pp. 1872-1874 ◽  
Author(s):  
Hikmet Akyazi ◽  
Davut Baltaci ◽  
Sevdegul Mungan ◽  
Ismail Hamdi Kara

Naproxen is a non-steroidal anti-inflammatory drug (NSAID) widely used for symptomatic relief of arthritis and other painful disorders, such as dysmenorrheal. Pruritus is the most common side effect of naproxen. Fixed drug eruption (FDE) due to naproxen is a rarely reported side-effect. No previous report has declared cross-reactivity between naproxen and other propionic acid derivatives. A 28-year-old man, presented with edematous and erythematous patchy lesion along with pruritus and inflammation on lip, have been suffering since 3 hours. It started after taking naproxen 550 mg for headache. On detailed inquiry, he defined similar symptom which recurred after whenever he took naproxen. Based on clinical and histopathological findings, it is evaluated as naproxen-induced FDE. We have tested cross-reactivity between naproxen and other propionic acid derivatives, and then we obtained negative result for oral provocation test with flurbiprofen. Here, we present a case of naproxen-induced FDE of 28-year-old man, by overviewing literatures.


2004 ◽  
Vol 8 (1) ◽  
pp. 16-18 ◽  
Author(s):  
N. Al-Mutairi ◽  
A. Al-Fouzan ◽  
Osama Nour-Eldin

Two females, one 28 years old and the other 32 years old, developed dusky red macules with pain and a burning sensation within 24 hours of receiving influenza vaccine. One patient had blisters within the lesion. A clinical diagnosis of fixed drug eruption (FDE) due to influenza vaccine was made. Histopathology was consistent with the diagnosis of FDE. The lesions subsided within 2 weeks of topical corticosteroid treatment. The diagnosis was confirmed by topical provocation test with influenza vaccine. A Medline search revealed these cases to be the second report of this kind of reaction due to influenza vaccine.


Author(s):  
Michael Makris ◽  
Christos Fokoloros ◽  
Anna Syrmali ◽  
Zoi Tsakiraki ◽  
Vasileia Damaskou ◽  
...  

Generalized bullous fixed drug eruption (GBFDE) is a specific variant of fixed drug eruption that belongs to severe cutaneous adverse reactions (SCARs) and its diagnosis is based mainly on clinical course and especially on the reoccurrence of typical bullous lesions in previous and new sites after re-administration of the offending drug. We present a well-documented case of fluconazole-induced GBFDE, with a positive patch test to fluconazole (30% weight/volume preparation) and clinical tolerance to itraconazole proven by negative oral provocation. Even in SCARs, patch testing represents a useful diagnostic tool, while oral provocation remains the gold standard in cases that an alternative but the chemically relevant drug must be administered.  


2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Da Woon Sim ◽  
Ji Eun Yu ◽  
Young-Il Koh

Abstract Background Erdosteine is used as a mucolytic agent and has a low incidence of adverse drug reactions, most of which are gastrointestinal and mild. Moreover, drug antigens rarely induce multiple simultaneous immunologic reactions. Only one previous case report has demonstrated hypersensitivity reaction induced by erdosteine. Here, we report a case of fixed drug eruption and anaphylaxis, which were concurrently induced by erdosteine. The association between the symptoms and erdosteine was proven by a drug provocation test. Case presentation A 35-year-old woman presented with recurrent angioedema and pruritic rash on the hands, which developed within 2 h following the administration of drugs, including erdosteine, for acute upper respiratory infection. Her rash was characterized by well-defined erythematous plaques, which recurred at the same site following the administration of the medications. She also experienced angioedema of the lips. Fixed drug eruption was considered after excluding other possible causes for the presented skin lesions. A drug provocation test confirmed that fixed drug eruption on both hands had occurred after administration of erdosteine, suggesting that erdosteine was the cause of the allergic reaction. However, she also experienced angioedema, isolated wheal, and laryngeal edema; thus, IgE-mediated type I hypersensitivity could also be concurrently occurring with the fixed drug eruption. Conclusions We report about a patient who was diagnosed with two different hypersensitivity reactions concurrently induced by erdosteine. We also demonstrate that patients may exhibit multiple simultaneous symptoms that usually arise from overlapping of different hypersensitivity mechanisms. Physicians should be aware of the possibility that some patients who are allergic to certain drugs could exhibit several symptoms caused by different mechanisms of hypersensitivity reactions simultaneously.


2011 ◽  
Vol 147 (2) ◽  
pp. 250 ◽  
Author(s):  
María Daniela Hermida ◽  
Lorena Consalvo ◽  
María Marta Lapadula ◽  
Patricia Della Giovanna ◽  
Hugo Néstor Cabrera

2002 ◽  
Vol 46 (6) ◽  
pp. 352-353 ◽  
Author(s):  
Sven Zedlitz ◽  
Lars Linzbach ◽  
Roland Kaufmann ◽  
Wolf-Henning Boehncke

2011 ◽  
Vol 23 (Suppl 3) ◽  
pp. S402 ◽  
Author(s):  
Hyun Jong Lee ◽  
Hei Sung Kim ◽  
Young Min Park ◽  
Hyung Ok Kim ◽  
Jun Young Lee

Sign in / Sign up

Export Citation Format

Share Document